Drug Details
| General Information of the Drug (ID: DR1036) | ||||
|---|---|---|---|---|
| Name |
Dicyclohexylcarbodiimide
|
|||
| Synonyms |
DICYCLOHEXYLCARBODIIMIDE; 538-75-0; N,N'-Dicyclohexylcarbodiimide; DCCD; 1,3-Dicyclohexylcarbodiimide; Carbodicyclohexylimide; DCCI; n,n-dicyclohexylcarbodiimide; Bis(cyclohexyl)carbodiimide; DCC; Cyclohexanamine, N,N'-methanetetraylbis-; n,n'-methanediylidenedicyclohexanamine; Carbodiimide, dicyclohexyl-; Dicylcohexylcarbodiimide; DCC Crosslinker; N,N'-Methanetetraylbiscyclohexaamine; N,N'-Dicyclohexylcarbodiimide (DCC); NSC 30022; dicyclohexylmethanediimine; N,N'-dicyclohexylmethanediimine; CHEBI:53090; dicyclohexyl carbodiimide; UNII-0T1427205E; Dicyclohexyl-Carbodiimide; MFCD00011659; N,N'-DICYCLOHEXYL-CARBODIIMIDE; n,n-dicychohexylcarbodiimide; n,n'-dicylohexylcarbodiimide; n,n-dichyclohexylcarbodiimide; n,n-dicyclohexyl carbodiimide; n,n'-dicyclohexyl carbodiimide; 0T1427205E; DSSTox_CID_3817; DSSTox_RID_77197; DSSTox_GSID_23817; Cyclohexanamine,N'-methanetetraylbis-; N,N'-Dicyclohexylcarbodiimide, 99%; CAS-538-75-0; Dicyclimide;1,3-dicyclohexylcarbodiimide;N,N-Dicyclohexylcarbodiimide;N,N'-Methanediylidenedicyclohexanamine; 1,3-dicyclohexyl-1,3-diazapropa-1,2-diene; EINECS 208-704-1; n,n'-dicyclohexylcarbodiimid; BRN 0610662; N,N'-dicyclohexylcarbodimide; AI3-08191; CCRIS 9266; HSDB 8049; dicyclohexylcarbodiimid; dicyclohexylcarbodimide; dicylohexylcarbodiimide; Dicylcohexylcarbodimide; dicyciohexylcarbodiimide; Dicyclohexyicarbodiimide; dicyclohexyl carbodimide; dicylohexyl-carbodiimide; PubChem12523; dicyclo-hexylcarbodiimide; dicyclohe-xylcarbodiimide; dicyclohexylcarbo-diimide; dicyclohexylcarbod iimide; dicyclohexylcarbodi-imide; ACMC-1ASTJ; Dicyclohexyl carbo diimide; Dicyclohexyl-carboxydilmide; SCHEMBL303; 1,3dicyclohexylcarbodiimide; Epitope ID:114067; EC 208-704-1; 1,3-dicyclohexylcarbodiimid; 1,3-dicyclohexylcarbodimide; 1.3-dicyclohexylcarbodimide; N,N'dicyclohexylcarbodiimide; 1,3-dicylcohexylcarbodiimide; 1.3-dicyclohexylcarbodiimide; N, N'dicyclohexylcarbodimide; 1,N'-dicyclohexylcarbodimide; n.n'-dicyclohexylcarbodiimide; N,N'-dicylcohexylcarbodiimide; 4-12-00-00072 (Beilstein Handbook Reference); 1, 3-dicyclohexylcarbodiimide; 1,3- dicyclohexylcarbodiimide; 1,3-dicyclo-hexylcarbodiimide; 1,3-dicyclohexyl carbodiimide; 1,3-dicyclohexyl-carbodiimide; 1,3-dicyclohexylcarbo-diimide; N, N'-dicyclohexylcarbodimide; N,N'-Dicyclohexyl carbodimide; n,n' dicyclohexyl carbodiimide; N, N'-dicyclohexylcarbodiimide; N,N'-dicyclo hexylcarbodiimide; N,N'-dicyclo-hexylcarbodiimide; 1,3-di-cyclohexyl carbodiimide; 1,3-dicyclo hexyl carbodiimide; 1,3-dicyclohexyl carbo-diimide; 1,3-dicyclohexyl- carbodiimide; CARBODIIMIDE,DICYCLOHEXYL; CHEMBL162598; N,N,-dichyclohexyl-carbodiimide; DTXSID1023817; N, N'-dicyclohexyl carbodiimide; N,N'- dicyclohexyl carbodiimide; N,N'-dicyclo hexyl carbodiimide; N.N' - dicyclohexylcarbodiimide; BDBM129231; ACT09818; DCC, 99%; Methanediimine, N,N'-dicyclohexyl-; NSC30022; NSC53373; NSC57182; ZINC8585900; DCC, 1.0 M in methylene chloride; Tox21_203000; Tox21_303237; ANW-31872; BBL012208; N,N'-Methanetetraylbiscyclohexanamine; NSC-30022; NSC-53373; NSC-57182; SBB059225; STL089892; AKOS000120067; US8815951, dicyclohexylcarbodiimide; AM83818; CS-W020097; MCULE-5242025177; N,N'-methanediylidene-dicyclohexanamine; US8815951, N/A; DCC, puriss., >=99.0% (GC); NCGC00091497-01; NCGC00091497-02; NCGC00091497-03; NCGC00091497-04; NCGC00257167-01; NCGC00260545-01; AK-43977; BP-13398; DB-002694; N-(N-cyclohexylcarboximidoyl)cyclohexanamine; D0436; D0437; FT-0629452; N-((cyclohexylimino)methylene)cyclohexanamine; ST50825552; N-((cyclohexylimino)methylene) cyclohexanamine; Cyclohexaamine, N,N'-methanetetraylbis- (9CI); 538D750; Q306565; Q-200966; Dicyclohexylcarbodiimide solution, 60 wt. % in xylenes; F0001-1397; N,N'-Dicyclohexylcarbodiimide, 1M solution in dichloromethane, AcroSeal(R)
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Prostate cancer [ICD-11: 2C82] | Investigative | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C13H22N2
|
|||
| PubChem CID | ||||
| Canonical SMILES |
C1CCC(CC1)N=C=NC2CCCCC2
|
|||
| InChI |
1S/C13H22N2/c1-3-7-12(8-4-1)14-11-15-13-9-5-2-6-10-13/h12-13H,1-10H2
|
|||
| InChIKey |
QOSSAOTZNIDXMA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 538-75-0
|
|||
| ChEBI ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Silibinin | Carduus marianus | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | Enterococcus faecium | Microorganism model | Enterococcus faecium | |||
| Escherichia coli | Microorganism model | Escherichia coli | ||||
| Pseudomonas aeruginosa | Microorganism model | Pseudomonas aeruginosa | ||||
| Experimental
Result(s) |
Silybin showed a remarkable synergistic activity in combination with some antibiotic agents against drug-resistant bacteria. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | STAT factor 3 (STAT3) | Molecule Info | [3] | |
| KEGG Pathway | Chemokine signaling pathway | Click to Show/Hide | ||
| 2 | HIF-1 signaling pathway | |||
| 3 | FoxO signaling pathway | |||
| 4 | Signaling pathways regulating pluripotency of stem cells | |||
| 5 | Jak-STAT signaling pathway | |||
| 6 | Prolactin signaling pathway | |||
| 7 | Adipocytokine signaling pathway | |||
| 8 | Toxoplasmosis | |||
| 9 | Hepatitis C | |||
| 10 | Hepatitis B | |||
| 11 | Measles | |||
| 12 | Epstein-Barr virus infection | |||
| 13 | Pathways in cancer | |||
| 14 | Viral carcinogenesis | |||
| 15 | Proteoglycans in cancer | |||
| 16 | MicroRNAs in cancer | |||
| 17 | Pancreatic cancer | |||
| 18 | Acute myeloid leukemia | |||
| 19 | Inflammatory bowel disease (IBD) | |||
| Panther Pathway | Angiogenesis | Click to Show/Hide | ||
| 2 | EGF receptor signaling pathway | |||
| 3 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| 4 | Interleukin signaling pathway | |||
| 5 | JAK/STAT signaling pathway | |||
| 6 | PDGF signaling pathway | |||
| 7 | Ras Pathway | |||
| 8 | CCKR signaling map ST | |||
| Pathway Interaction Database | GMCSF-mediated signaling events | Click to Show/Hide | ||
| 2 | IL27-mediated signaling events | |||
| 3 | Signaling events mediated by PTP1B | |||
| 4 | IL12-mediated signaling events | |||
| 5 | Signaling events mediated by TCPTP | |||
| 6 | Signaling events mediated by HDAC Class I | |||
| 7 | IL2-mediated signaling events | |||
| 8 | CXCR4-mediated signaling events | |||
| 9 | EGF receptor (ErbB1) signaling pathway | |||
| 10 | IFN-gamma pathway | |||
| 11 | ErbB1 downstream signaling | |||
| 12 | ErbB2/ErbB3 signaling events | |||
| 13 | IL6-mediated signaling events | |||
| 14 | PDGFR-beta signaling pathway | |||
| 15 | Neurotrophic factor-mediated Trk receptor signaling | |||
| 16 | IL23-mediated signaling events | |||
| 17 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
| 18 | FGF signaling pathway | |||
| 19 | RAC1 signaling pathway | |||
| 20 | Notch-mediated HES/HEY network | |||
| 21 | IL12 signaling mediated by STAT4 | |||
| Reactome | Interleukin-6 signaling | Click to Show/Hide | ||
| 2 | Senescence-Associated Secretory Phenotype (SASP) | |||
| 3 | POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | |||
| 4 | Transcriptional regulation of pluripotent stem cells | |||
| 5 | Growth hormone receptor signaling | |||
| WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | Click to Show/Hide | ||
| 2 | Notch Signaling Pathway | |||
| 3 | Interferon type I signaling pathways | |||
| 4 | EPO Receptor Signaling | |||
| 5 | TGF Beta Signaling Pathway | |||
| 6 | IL-2 Signaling Pathway | |||
| 7 | EGF/EGFR Signaling Pathway | |||
| 8 | IL-4 Signaling Pathway | |||
| 9 | IL-6 signaling pathway | |||
| 10 | Signaling of Hepatocyte Growth Factor Receptor | |||
| 11 | Kit receptor signaling pathway | |||
| 12 | Nuclear Receptors Meta-Pathway | |||
| 13 | Estrogen Receptor Pathway | |||
| 14 | TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | |||
| 15 | IL-3 Signaling Pathway | |||
| 16 | Dopaminergic Neurogenesis | |||
| 17 | Transcriptional regulation of pluripotent stem cells | |||
| 18 | Mammary gland development pathway - Involution (Stage 4 of 4) | |||
| 19 | Signaling by SCF-KIT | |||
| 20 | Interleukin-6 signaling | |||
| 21 | Growth hormone receptor signaling | |||
| 22 | JAK/STAT | |||
| 23 | PDGF Pathway | |||
| 24 | BDNF signaling pathway | |||
| 25 | Oncostatin M Signaling Pathway | |||
| 26 | Adipogenesis | |||
| 27 | Interleukin-11 Signaling Pathway | |||
| 28 | AGE/RAGE pathway | |||
| 29 | Prostate Cancer | |||
| 30 | TSLP Signaling Pathway | |||
| 31 | IL-9 Signaling Pathway | |||
| 32 | IL17 signaling pathway | |||
| 33 | IL-7 Signaling Pathway | |||
| 34 | Regulation of Microtubule Cytoskeleton | |||
| 35 | Leptin signaling pathway | |||
| 36 | TSH signaling pathway | |||
| 37 | Cell Differentiation - Index | |||
| 38 | Cell Differentiation - meta | |||
| 39 | Signaling by PDGF | |||
| 40 | NGF signalling via TRKA from the plasma membrane | |||
| 41 | TFs Regulate miRNAs related to cardiac hypertrophy | |||
| 42 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 43 | Physiological and Pathological Hypertrophy of the Heart | |||
| 44 | Androgen receptor signaling pathway | |||
| 45 | IL-5 Signaling Pathway | |||
